WO2020186747A1 - 一种冻干制剂及其制备方法和应用 - Google Patents
一种冻干制剂及其制备方法和应用 Download PDFInfo
- Publication number
- WO2020186747A1 WO2020186747A1 PCT/CN2019/112445 CN2019112445W WO2020186747A1 WO 2020186747 A1 WO2020186747 A1 WO 2020186747A1 CN 2019112445 W CN2019112445 W CN 2019112445W WO 2020186747 A1 WO2020186747 A1 WO 2020186747A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- freeze
- preparation
- binder
- saponins
- triterpene
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 197
- 239000000203 mixture Substances 0.000 title claims abstract description 117
- 238000009472 formulation Methods 0.000 title abstract description 16
- 239000011230 binding agent Substances 0.000 claims abstract description 94
- 239000007787 solid Substances 0.000 claims abstract description 23
- 235000013361 beverage Nutrition 0.000 claims abstract description 22
- 238000004108 freeze drying Methods 0.000 claims abstract description 11
- 238000005406 washing Methods 0.000 claims abstract description 8
- 230000007423 decrease Effects 0.000 claims abstract description 3
- 229930182493 triterpene saponin Natural products 0.000 claims description 148
- 239000000243 solution Substances 0.000 claims description 104
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 101
- 239000000463 material Substances 0.000 claims description 72
- 229930182490 saponin Natural products 0.000 claims description 69
- 235000017709 saponins Nutrition 0.000 claims description 69
- 150000007949 saponins Chemical class 0.000 claims description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 239000002904 solvent Substances 0.000 claims description 45
- 239000000284 extract Substances 0.000 claims description 41
- 238000004090 dissolution Methods 0.000 claims description 40
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 33
- 240000005373 Panax quinquefolius Species 0.000 claims description 31
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 31
- 239000004480 active ingredient Substances 0.000 claims description 29
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 28
- 241000756943 Codonopsis Species 0.000 claims description 28
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 28
- 239000011347 resin Substances 0.000 claims description 24
- 229920005989 resin Polymers 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 23
- 241000196324 Embryophyta Species 0.000 claims description 22
- 239000012535 impurity Substances 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 21
- 239000012141 concentrate Substances 0.000 claims description 20
- 239000000796 flavoring agent Substances 0.000 claims description 20
- 235000019634 flavors Nutrition 0.000 claims description 20
- 238000004809 thin layer chromatography Methods 0.000 claims description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 18
- 235000008434 ginseng Nutrition 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 16
- 229920001282 polysaccharide Polymers 0.000 claims description 16
- 239000005017 polysaccharide Substances 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 16
- 230000002378 acidificating effect Effects 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000001569 carbon dioxide Substances 0.000 claims description 14
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 14
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 11
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 11
- 241000180649 Panax notoginseng Species 0.000 claims description 11
- 229910052782 aluminium Inorganic materials 0.000 claims description 10
- 238000011049 filling Methods 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 229930187479 gypenoside Natural products 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 230000004888 barrier function Effects 0.000 claims description 8
- 229920003086 cellulose ether Polymers 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 235000006533 astragalus Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229930182494 ginsenoside Natural products 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 125000000346 malonyl group Chemical group C(CC(=O)*)(=O)* 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 229920003023 plastic Polymers 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 7
- CCDRPBGPIXPGRW-JNKODXNQSA-N (4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CCDRPBGPIXPGRW-JNKODXNQSA-N 0.000 claims description 6
- 229930188701 Astersaponin Natural products 0.000 claims description 6
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 6
- 241000202726 Bupleurum Species 0.000 claims description 6
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 6
- 241000208966 Polygala Species 0.000 claims description 6
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 6
- 239000006227 byproduct Substances 0.000 claims description 6
- 238000007872 degassing Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229940010454 licorice Drugs 0.000 claims description 6
- 235000019426 modified starch Nutrition 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 241001061264 Astragalus Species 0.000 claims description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000003607 modifier Substances 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 4
- 240000007643 Phytolacca americana Species 0.000 claims description 4
- 235000009074 Phytolacca americana Nutrition 0.000 claims description 4
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 4
- 210000003056 antler Anatomy 0.000 claims description 4
- 230000005496 eutectics Effects 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 239000003349 gelling agent Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- TZSYJZBVJYXHEK-SNQGWRGYSA-N platycoside E Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O TZSYJZBVJYXHEK-SNQGWRGYSA-N 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 2
- 241000251511 Holothuroidea Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 235000019206 astragalus extract Nutrition 0.000 claims description 2
- 235000020710 ginseng extract Nutrition 0.000 claims description 2
- 235000020717 hawthorn extract Nutrition 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 4
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 241000191896 Rana sylvatica Species 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000000729 antidote Substances 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 150000005856 steroid saponins Chemical group 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 4
- 150000008130 triterpenoid saponins Chemical class 0.000 abstract 6
- -1 terpene saponins Chemical class 0.000 description 23
- 150000004804 polysaccharides Chemical class 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 229920002907 Guar gum Polymers 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 6
- 235000010417 guar gum Nutrition 0.000 description 6
- 239000000665 guar gum Substances 0.000 description 6
- 229960002154 guar gum Drugs 0.000 description 6
- 229920000591 gum Polymers 0.000 description 6
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229930002600 steroidal saponin Natural products 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- NTYAVUNEPXGZQJ-UHFFFAOYSA-N 6''-Malonylginsenoside Rd1 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(COC(=O)CC(O)=O)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O NTYAVUNEPXGZQJ-UHFFFAOYSA-N 0.000 description 4
- NTYAVUNEPXGZQJ-LUSMHSHMSA-N CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4O[C@H](COC(=O)CC(O)=O)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C Chemical compound CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4O[C@H](COC(=O)CC(O)=O)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C NTYAVUNEPXGZQJ-LUSMHSHMSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000004368 Modified starch Substances 0.000 description 4
- LPAJXALQNMJKEJ-UHFFFAOYSA-N aster saponin Hb Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CCC(OC8OC(C(O)C(O)C8O)C(=O)O)C(C)(C)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1O LPAJXALQNMJKEJ-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 229920005615 natural polymer Polymers 0.000 description 4
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 4
- 239000011049 pearl Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 240000003183 Manihot esculenta Species 0.000 description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 229930189407 platycodin Natural products 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 229920004439 Aclar® Polymers 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 241000007126 Codonopsis pilosula Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 229930190792 Phytolaccasaponin Natural products 0.000 description 2
- 235000006751 Platycodon Nutrition 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- YQKCHRBAJSATCG-UHFFFAOYSA-N UNPD30744 Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC(C)(CCC=C(C)C)C2C3C(C4(CCC5C(C)(C)C(OC6C(C(O)C(O)C(CO)O6)OC6C(C(O)C(O)C(CO)O6)O)CCC5(C)C4CC3O)C)(C)CC2)O1 YQKCHRBAJSATCG-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000008373 coffee flavor Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 description 2
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- UVBLDLGZDSGCSN-UHFFFAOYSA-N ginsenoside-Rb3 Natural products C1=CC2C3(C)CCC(O)C(C)(C)C3CCC2(C)C2(C)CCC34CCC(C)C(C)C4C21OC3=O UVBLDLGZDSGCSN-UHFFFAOYSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229930189914 platycodon Natural products 0.000 description 2
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VROXGHAYIJKBCN-UHFFFAOYSA-N 1,1,1,9,9,9-hexahydroxynonan-5-one Chemical compound OC(CCCC(=O)CCCC(O)(O)O)(O)O VROXGHAYIJKBCN-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- SDXHBDVTZNMBEW-UHFFFAOYSA-N 1-ethoxy-2-(2-hydroxyethoxy)ethanol Chemical compound CCOC(O)COCCO SDXHBDVTZNMBEW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FWCWPAUCBWOOGG-HCSCSRTKSA-N 3-[[(2R,3S,4S,5R,6S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid Chemical compound CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](COC(=O)CC(O)=O)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C FWCWPAUCBWOOGG-HCSCSRTKSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical class C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000751139 Beauveria bassiana Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000972296 Choiromyces meandriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- FWCWPAUCBWOOGG-UHFFFAOYSA-N Malonylginsenoside Rb2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(COC(=O)CC(O)=O)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O FWCWPAUCBWOOGG-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100462438 Mus musculus Otulin gene Proteins 0.000 description 1
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 235000004500 Scoparia dulcis Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000042 carbacrylic resin Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 1
- 239000008370 chocolate flavor Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- QLVARBCGUNCRTA-LOYHVIPDSA-N ditetradecyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCCCCCCCCCCCCCOC(=O)[C@H](O)[C@@H](O)C(=O)OCCCCCCCCCCCCCC QLVARBCGUNCRTA-LOYHVIPDSA-N 0.000 description 1
- WWYHAQDAMPXWSI-UHFFFAOYSA-N dodecan-1-ol;methane Chemical compound C.CCCCCCCCCCCCO WWYHAQDAMPXWSI-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- NODILNFGTFIURN-USYOXQFSSA-N ginsenoside Rb3 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-USYOXQFSSA-N 0.000 description 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000019823 konjac gum Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- SABMMBQQLJBUGT-UHFFFAOYSA-N malonylginsenoside Ra3 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(OC3OCC(O)C(O)C3O)C2O)C(O)C(O)C1O)C4CCC5(C)C4C(O)CC6C7(C)CCC(OC8OC(CO)C(O)C(O)C8OC9OC(COC(=O)CC(=O)O)C(O)C(O)C9O)C(C)(C)C7CCC56C)C SABMMBQQLJBUGT-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Definitions
- the invention relates to the technical field of preparations, in particular to a freeze-dried preparation and a preparation method and application thereof.
- Freeze-dried preparations are medicinal ingredients (raw materials) and auxiliary ingredients (adjuvants), dissolved in a solvent (such as water), formulated into a certain concentration of pre-incubation, and then frozen in a sterile airtight environment at a low temperature, and then reduced
- a solvent such as water
- the method of slowly increasing the temperature of the product under the ambient air pressure makes the solvent (such as water) in the product sublimate, leaving a solid form of loose block or powdered medicine.
- Triterpene saponins are a class of natural pharmaceutical chemical components, which have the characteristics of complex structure, low content, and strong pharmacological activity. Many of these components are easily soluble in water and heat sensitive. Compared with steroidal saponins, three The acidic saponins in terpene saponins are basically only found in fresh materials due to their thermal instability. During the processing of the product, the acidic saponins are converted to steroidal saponins, so they are difficult to store and are rarely used in actual products. .
- triterpene saponins have many pharmacological activities, such as hypoglycemic and lipid-lowering.
- pharmacological activities such as hypoglycemic and lipid-lowering.
- most of the triterpene saponins have been identified and obtained structural information, and they are mostly realized through artificial synthesis.
- the way of obtaining artificial synthesis is greatly improved.
- the cost, residues of solvents and intermediate products in the synthetic route, and the control of impurities will all become safety hazards.
- triterpene saponins The conventional application of triterpene saponins is the treatment of cardiovascular diseases, and it is clinically used in injections, oral tablets, capsules and other dosage forms.
- acidic saponins in triterpene saponins are subject to many limitations in terms of processing technology and storage due to their thermal instability.
- the purpose of the present invention is to solve the problems of low drug loading, poor disintegration and dissolution, and slow dissolution of the freeze-dried preparations existing in the prior art, and to provide a freeze-dried preparation that includes triterpene saponins and viscosities.
- the disintegration time is less than 3s, and the dissolution amount within 1 minute is greater than 90%;
- the disintegration time is less than 10s, and the dissolution time Less than 15s, the dissolution rate is greater than 90% in 1 min.
- Another aspect of the present invention is to provide a preparation method of the freeze-dried preparation, which is prepared by direct freeze-drying or soft-ice freeze-drying, and has a simple process and is convenient for commercial promotion and application.
- Another aspect of the present invention is to provide the application of the freeze-dried preparation, which can be applied to the fields of daily chemicals, medicines, health care products and food.
- Another aspect of the present invention is to provide a method for extracting triterpene saponins, which does not damage the pharmacological activity of triterpene saponins, and has the advantage of large extraction volume.
- 0.24-0.54g of saponin-containing medicinal materials can be extracted per 1g.
- Acidic saponins, and the extraction method has production feasibility, and can further process freeze-dried preparations with corresponding functions.
- a freeze-dried preparation wherein the mass percentage of the triterpene saponins in the freeze-dried preparation is 0.004-95%, and the mass percentage of the binder in the freeze-dried preparation is 0.01-99%;
- the freeze-dried preparation is made by freeze-drying a pre-preparation solution containing triterpene saponin and a binder:
- the mass percentage of triterpene saponins in the pre-preparation solution is 0.001%-50%
- the mass percentage of the binder in the pre-preparation solution is 0.01%-50%
- the mass of triterpene saponins increases with the mass of the binder Increase with the increase
- the mass percentage of triterpene saponins in the pre-preparation solution is 50%-95%
- the mass percentage of the binder in the pre-preparation solution is 0.01%-20%
- the mass of triterpene saponins varies with the binder The quality increases and decreases.
- a lyophilized preparation is formed by lyophilizing a pre-preparation solution containing triterpene saponin and a binder, and the lyophilized preparation is an oral preparation, a solid beverage or a non-washing skin care product.
- the mass percentage of triterpene saponin in the pre-preparation solution is 0.004%-50%, and the mass percentage of the binder in the pre-preparation solution is 0.01%-50%
- the mass percentage of triterpene saponin in the pre-preparation solution is 0.004%-30%, and the mass percentage of the binder in the pre-preparation solution is 0.01%-35%, more preferably, the triterpene
- the mass percentage of saponin in the pre-preparation solution is 0.004%-20%, and the mass percentage of the binder in the pre-preparation solution is 0.01%-30%. More preferably, the mass percentage of triterpene saponin in the pre-preparation solution is 10%-20%, and the mass percentage of the binder in the pre-preparation solution is 1%-10%.
- the mass percentage of triterpene saponin in the pre-preparation solution is 50%-95%, and the binder is in the pre-preparation solution
- the mass percentage is 0.01%-20%.
- the mass percentage of triterpene saponins in the pre-preparation solution is 50%-85%, and the mass percentage of the binder in the pre-preparation solution is 0.01%-20%.
- the triterpene saponins are The mass percentage in the pre-preparation solution is 50%-80%, and the mass percentage of the binder in the pre-preparation solution is 0.01%-20%. More preferably, the mass percentage of triterpene saponin in the pre-preparation solution is 70%-80%, and the mass percentage of the binder in the pre-preparation solution is 0.01%-10%.
- the mass percentage of triterpene saponins in the pre-preparation solution is 0.004-30%, and the binder is in the The mass percentage in the aforementioned liquid preparation is 0.01-50%.
- the mass percentage of triterpene saponin in the pre-preparation solution is 0.004-10%, and the mass percentage of the binder in the pre-preparation solution is 0.01-10%.
- the terpene saponins are in the The mass percentage in the pre-preparation solution is 0.004-0.1%, and the mass percentage of the binder in the pre-preparation solution is 0.01-3%.
- the disintegration time of the oral preparation is less than 3s, the dissolution amount in 1 minute is greater than 90%, the disintegration time of the solid beverage is less than 10s, the dissolution time is less than 15 seconds, and the dissolution amount in 1 minute is greater than 90%.
- the lyophilized preparation When used as an oral preparation, it can realize entrance disintegration (0.1-0.3ml of saliva, disintegration within 3s) and rapid dissolution (over 90% within 1 min); as a solid beverage (including granules, instant tablets, etc.) When put into water (water temperature is 20°C ⁇ 50°C), it still disintegrates rapidly (disintegrates within 10s), and dissolves quickly and uniformly (no particles can be seen within 15s), and dissolves rapidly (over 90% within 1min).
- the freeze-dried preparation also includes auxiliary materials, the mass percentage of the auxiliary materials in the pre-preparation solution is 0.01-50%, and the auxiliary materials are framework support agents, disintegrants, skin feel modifiers, and antioxidants , Flavors, flavors, transmucosal, transdermal absorption enhancers or pH regulators in one or more combinations.
- the backbone support agent is sugar (such as maltose, trehalose, microcrystalline cellulose), sugar alcohol (such as mannitol, sorbitol, xylitol), 2-12 carbon atoms of amino acids (such as glycine, alanine) , Glutamic acid, etc.) and inorganic salts (such as sodium phosphate, aluminum silicate, etc.), dextrin (maltodextrin), or a combination thereof;
- the disintegrant is selected from effervescent agents, anhydrous lactose, starch and amylase , Cellulose and cellulase, gum and hemicellulase, gelatin and protease, alginate, carrageenase, sucrose and invertase one or several mixtures;
- the skin feel modifier Is polymethyl silsesquioxane, tapioca starch, modified tapioca starch, corn starch, modified corn starch, pearl powder, si
- the transdermal absorbent is selected from any one or a mixture of azone, lecithin, and ethoxydiethylene glycol
- the pH regulator is selected from lemon Acid, sorbic acid, tartaric acid, lactic acid, malic acid, sodium bicarbonate, sodium carbonate, disodium hydrogen phosphate, calcium phosphate, potassium phosphate, trimagnesium phosphate, etc., or a mixture of several.
- the binder is composed of a freeze-dried binder and/or a low-temperature binder;
- the freeze-dried binder is selected from artificial or natural polymer, modified artificial or natural polymer
- the agent is one or a combination of C1-C16 alcohol, oil, surfactant, artificial or natural high molecular polymer or modified artificial or natural high molecular polymer.
- the artificial or natural polymer is selected from collagen, gelatin, hydrolyzed gelatin, hydrolyzed collagen, gum arabic, xanthan gum, soy protein gum, sclerotium gum, bio-carbohydrate gum, carrageenan, guar gum, and Cold gum, pectin, konjac gum, carrageenan, locust bean gum, gum, alginic acid, sodium alginate, agar, polyvinyl alcohol methyl acrylate graft copolymer, carbomer, carbo resin, polyethylene Pyrrolidone, polyvinyl alcohol and its derivatives, polyethylene glycol and its derivatives, polyethylene oxide, polyacrylamide, sodium polyacrylate, polyacrylate, polyacrylic acid and its derivatives, or combinations thereof; modified artificial Or the natural polymer can be modified arabic gum, modified xanthan gum, modified guar gum, modified pectin, modified sodium polyacrylate and its grafted starch, modified paraffin, or a combination thereof .
- the freeze-dried preparation also includes active ingredients, the mass percentage of the active ingredients in the pre-preparation solution is 0.01-50%, and the active ingredients are steroidal saponin, astragalus extract, ginseng extract, One of American ginseng extract, Gynostemma pentaphyllum extract, flavone, ginseng polysaccharide, sea cucumber polysaccharide, amino acid, notoginseng element, velvet antler polypeptide, resveratrol, pearl powder, hydrolyzed pearl, forest frog oil extract, SOD or hawthorn extract Or multiple combinations.
- active ingredients are steroidal saponin, astragalus extract, ginseng extract, One of American ginseng extract, Gynostemma pentaphyllum extract, flavone, ginseng polysaccharide, sea cucumber polysaccharide, amino acid, notoginseng element, velvet antler polypeptide, resveratrol, pearl powder, hydrolyzed pearl, forest frog oil extract, SOD
- the triterpene saponins are acidic heat-sensitive saponins, preferably malonyl ginsenosides, astragaloside, platycodin E, codonopsis saponins AG, aster saponins, Hb codonopsis saponins I-III or Gynostemma pentaphyllum One or a combination of saponin.
- Acidic heat-sensitive saponins refer to triterpene saponins with a carboxyl group in the structure and the loss rate is greater than 30% when the heating temperature is higher than 50°C. For acidic heat-sensitive saponins with high sensitivity, the loss rate can be reached after heating for 1-10 minutes 30%. For acidic heat-sensitive saponin with a slightly lower sensitivity, the loss rate can reach 30% after heating for 1-48 hours.
- the triterpene saponins are purified from saponin-containing medicinal materials by using carbon dioxide supercritical extraction process and macroporous resin exchange adsorption process (the extraction rate of triterpene saponins is 80-90%), which includes the following step:
- the saponin-containing medicinal material is one plant or a combination of multiple plants among American ginseng, ginseng, Panax notoginseng, Gynostemma pentaphyllum, Bupleurum, Codonopsis, Platycodon grandiflorum, Polygala, licorice or Pokeweed, and the saponin-containing medicinal material It is one or a combination of plant roots, stems and leaves or flowers.
- the saponin-containing medicinal materials are American ginseng roots, panax notoginseng roots, ginseng roots, ginseng flowers and panax notoginseng flower leaf stems.
- freeze-dried preparation is prepared by the following method:
- freeze-dry the mixture 5 to obtain a freeze-dried preparation (freeze-dried excipient preparation).
- the freeze-dried preparation may be, but not limited to, a tablet shape, a spherical shape, an ellipsoidal shape, or various characters, animals, plants, food, graphic logos or cartoon images.
- Another aspect of the present invention also includes the application of the freeze-dried preparation in daily chemicals, medicines, health products and foods.
- it also includes a barrier package whose content is the lyophilized preparation.
- the barrier packaging is a blister pack made of double aluminum, aluminum plastic or high barrier polymer material, a glass or metal container with aluminum plastic seal or film seal, or a sealed container made of metal.
- the aluminum-plastic material is a composite material of PVDC, Aclar, EVOH and AL, or a composite material of aluminum and PP, PE, PET and PVC)
- the high barrier polymer material is PVDC, Aclar, EVOH
- the sealed container can be a box, can, Bottles, such as cans, aluminum cans, stainless steel cans, etc. Or it can be capsule coffee or small aluminum bowl.
- Another aspect of the present invention also includes the application of triterpene saponins in freeze-dried preparations.
- the triterpene saponins are heat-sensitive acidic saponins, and the heat-sensitive acidic saponins have carboxyl groups in the structure and the heating temperature is higher than 50°C.
- the loss rate of triterpene saponins is greater than 30%. For acidic heat-sensitive saponins with high sensitivity, the loss rate can reach 30% after heating for 1-10 minutes, and for acidic heat-sensitive saponins with slightly lower sensitivity, the loss rate can reach 30% after heating for 1-48h.
- Another aspect of the present invention also includes the application of triterpene saponins in freeze-dried preparations.
- the triterpene saponins are purified from saponin-containing medicinal materials by using carbon dioxide supercritical extraction process and macroporous resin exchange adsorption process, which include The following steps:
- the saponin-containing medicinal material is one plant or a combination of multiple plants of American ginseng, ginseng, Panax notoginseng, Gynostemma pentaphyllum, Bupleurum, Codonopsis, Platycodon, Polygala, Licorice, Astragalus or Phytolacca Saponin medicinal materials are one or a combination of roots, stems and leaves or flowers of plants.
- a method for extracting triterpene saponins includes the following steps:
- the content of triterpene saponins in saponin-containing medicinal materials is generally 30-60%.
- 80-90% of triterpene saponin in saponin-containing medicinal materials can be extracted, and the extraction rate is high.
- the saponin-containing medicinal material is one plant or a combination of multiple plants of American ginseng, ginseng, Panax notoginseng, Gynostemma pentaphyllum, Bupleurum, Codonopsis, Platycodon, Polygala, Licorice, Astragalus or Phytolacca Saponin medicinal materials are one or a combination of roots, stems and leaves or flowers of plants.
- Another aspect of the present invention also includes a method for preparing a freeze-dried formulation, including the following steps:
- the freeze-dried preparation of the present invention has the advantage of fast disintegration as an oral agent, and the disintegration time is less than 3s.
- the disintegration time is less than 3s, the dissolution time is less than 10s, and the amount of dissolution within 1 min is greater than 90%.
- the saponins proposed from saponin-containing medicinal materials can maintain good pharmacological properties, and after being added to the lyophilized agent, they can still retain good pharmacological properties, such as hypoglycemic, Lipid-lowering, etc., solved the problem of artificial synthesis of triterpene saponins.
- Figure 1 shows the malonyl ginsenoside HPLC-MS total ion current chromatogram of the extract.
- a method for extracting triterpene saponins including the following steps:
- step 4) and step 5) are mixed to obtain the malonyl ginsenoside HPLC-MS total ion chromatogram shown in FIG. 1.
- malonyl ginsenosides Rg1, Re, Rf, Rb1, Rc, Rb2, Rb3 and Rd can also be obtained.
- a method for extracting triterpene saponins including the following steps:
- a method for extracting triterpene saponins including the following steps:
- the astragaloside (X, XIV, XV, XVI) obtained in group C was verified by HPLC-MS, and the total ion current chromatogram obtained was consistent with the standard spectrum reported in related literature.
- a method for extracting triterpene saponins including the following steps:
- HPLC-MS was used to verify the Codonopsis A-G, Aster Saponins Hb and Codonopsis I-III obtained in Group C experiments, and the total ion current chromatogram obtained was consistent with the standard spectrum reported in related literature.
- a freeze-dried preparation the freeze-dried preparation is used as an oral preparation
- the triterpene saponin in the freeze-dried preparation is malonyl ginsenoside Re with a percentage of 10%
- the binder is sprouting enzyme polysaccharide, which The percentage content is 3%.
- the freeze-dried formulation is prepared by the following steps:
- the oral preparation has the function of lowering blood sugar, the disintegration time is within 3s, and the dissolution rate is within 30s, and the dissolution rate is 95%.
- the malonyl ginsenoside Re is replaced with other types of malonyl ginsenosides, and the oral preparations obtained have the same properties.
- the disintegration time is within 3s, and the dissolution rate is within 30s.
- the dissolution rate can reach 95 %.
- the content of malonyl ginsenoside Re is modified to 0.004%
- the content of sprouting enzyme polysaccharide is 0.01%
- the content of malonyl ginsenoside Re is 50%
- the content of sprouting enzyme polysaccharide is 50% of the oral preparations have the same effect.
- a freeze-dried preparation for use as an oral preparation is 10% malonyl ginsenoside Rg1 and 20% malonyl ginsenoside Rb1, a total of 30%, binder Guar gum (the percentage is 0.5%) and butylene glycol (the percentage is 15%); the auxiliary material is the skeleton support agent (modified tapioca starch), and the percentage is 5%.
- the disintegration time of the oral preparation is within 3s, and the dissolution rate is 95% within 30s.
- the freeze-dried formulation is prepared by the following steps:
- the oral preparation has the function of lowering blood pressure and lipid, the disintegration time is within 3s, and the dissolution rate is within 30s, and the dissolution rate is 95%.
- the triterpene saponins are modified to 0.002% malonyl ginsenoside Rg1 and 0.002% malonyl ginsenoside Rb1, guar gum (the percentage is 0.005%), and butylene glycol (the percentage is 0.005%), or modify the triterpene saponins to 20% malonyl ginsenoside Rg1 and 10% malonyl ginsenoside Rb1, guar gum (20%) and butylene glycol (15%) %), the oral preparations of the same properties were obtained.
- a freeze-dried preparation the freeze-dried preparation is used as an oral preparation
- the triterpene saponin in the freeze-dried preparation is platycodin E30%
- the binder is modified starch (the percentage is 30%)
- the auxiliary material is an antioxidant ( Vitamin C, its percentage content is 7%)
- the active ingredient is ginseng polysaccharide (the percentage content is 5%).
- the disintegration time of the oral preparation is within 3s, and the dissolution rate is 90% within 50s.
- the freeze-dried formulation is prepared by the following steps:
- a) Prepare a soft ice mixture: mix Platycodin E, modified starch, vitamin C and water according to a set ratio to obtain a pre-preparation solution; freeze the pre-preparation solution to obtain a soft ice mixture;
- Ginseng polysaccharide is used as dry powder
- the oral preparation has a cardiovascular care function, the disintegration time is within 3s, and the dissolution rate is 93% within 30s.
- the triterpene saponins are modified to be Platycodin E10%, modified starch (1% content); the auxiliary material is antioxidant (vitamin C, the percentage content is 0.01%), and the active ingredient is ginseng polysaccharide ( The percentage content is 50%), or the triterpene saponin is platycodin E20%, modified starch (the percentage content is 10%); the auxiliary material is antioxidant (vitamin C, the percentage content is 50%), active
- the composition is ginseng polysaccharide (the percentage content is 0.01%), and oral preparations with the same properties can be obtained.
- the disintegration time of oral preparations can be less than 3s and the dissolution in 1min The amount is greater than 90%.
- a freeze-dried preparation which is used as a solid beverage (both granules or instant tablets) and has a lipid-lowering function.
- the triterpene saponin in the freeze-dried preparation is Codonopsis A (70%)
- the binder is sodium hyaluronate (10% content).
- the disintegration time of the solid beverage is 8 seconds, the dissolution time is less than 12 seconds, and the dissolution amount within 30 seconds is greater than 90%.
- the freeze-dried formulation is prepared by the following steps:
- Codonopsis A or polyamino acid After mixing water, Codonopsis A or polyamino acid according to the set ratio to form a pre-mixed solution, make the volume constant and degas;
- modify the triterpene saponins to Codonopsis saponins A (percentage is 50%), and the binder is sodium hyaluronate (percentages are 20%), or modify the triterpene saponins to Codonopsis saponins A (95% in percentage), and sodium hyaluronate (0.01% in percentage) as the binder, can obtain solid beverages with the same properties.
- a freeze-dried preparation which is used as a solid beverage (both granules or instant tablets) and has the function of reducing blood pressure; the triterpene saponin in the freeze-dried preparation is gypenoside (95%), which is viscous
- the binding agent is polyamino acid (percentage is 1%), and the auxiliary material is pH regulator (citric acid, the percentage is 1%) and flavor (coffee flavor, the percentage is 1%).
- the disintegration time of the solid beverage is 6 seconds, the dissolution time is less than 10 seconds, and the dissolution amount within 30 seconds is greater than 95%.
- the freeze-dried formulation is prepared by the following steps:
- a) Prepare a soft ice mixture: add gypenoside, polyamino acid, pH adjuster and flavor according to a set ratio to obtain a pre-mixed solution, and freeze the pre-mixed solution to obtain soft ice mixture 1;
- modify gypenoside (percentage content is 85%), the binder is polyamino acid (percentage content is 0.01%), or modify gypenoside (percentage content is 50%), binding
- the agent is polyamino acid (percentage content is 20%), and solid beverages with the same properties can be obtained.
- a freeze-dried preparation which is used as a solid beverage (both granules or instant tablets) and has an anti-fatigue function;
- the triterpene saponin in the freeze-dried preparation is aster saponin Hb (80% content)
- the binder is an inorganic gel (percentage is 10%)
- the auxiliary material is sodium carboxymethyl starch (percentage is 2%)
- the active ingredient is arginine (the percentage is 1%) and velvet antler Polypeptide (1% content).
- the disintegration time of the solid beverage is 5s, the dissolution time is less than 12s, and the dissolution amount in 50s is greater than 95%.
- the freeze-dried formulation is prepared by the following steps:
- a) Prepare a soft ice mixture: mix aster saponin Hb, sodium carboxymethyl starch and water according to a set ratio to obtain a pre-preparation solution; freeze the pre-preparation solution to obtain a soft ice mixture;
- modify aster saponin Hb (percentage content is 70%), and the binder is inorganic gelling agent (percentage content is 10%), or modify aster saponin Hb (percentage content is 80%). %), the binder is an inorganic gelling agent (the percentage content is 0.01%), and solid beverages with the same properties can be obtained.
- a freeze-dried preparation which is used as a non-washing and care skin care product (specifically whitening and anti-aging essence), and has the function of whitening and anti-aging;
- the triterpene saponin in the freeze-dried preparation is Codonopsis lanceolata saponin I (100 The content is 0.1%)
- the binder is cellulose ethers (the percentage is 2%)
- the auxiliary materials are transdermal absorption enhancers (the percentage is 0.2%) and skin feel modifiers (the percentage is 5 %)
- the active ingredients are steroidal saponins (the percentage is 0.1%) and hydrolyzed pearls (the percentage is 1%).
- the disintegration time of the non-wash and care skin care product is 5s, the dissolution time is less than 12s, and the dissolution amount within 50s is greater than 95%.
- the freeze-dried formulation is prepared by the following steps:
- a) Prepare a soft ice mixture: mix Codonopsis lanceolata saponins I, cellulose ethers, and water in a set proportion to obtain a pre-preparation solution; freeze the pre-preparation solution to obtain a soft ice mixture;
- transdermal absorption enhancers b) Use transdermal absorption enhancers, skin feel modifiers, steroidal saponins and hydrolyzed pearls as dry powders;
- this non-washing skin care product When using this non-washing skin care product, dissolve it with 1-3ml of water, lotion or essence to obtain essence, cream or body lotion, and apply it on the epidermis of the corresponding position on the body, which has the effect of whitening and anti-aging.
- modify the triterpene saponins to Codonopsis lanceolata saponins I (percentage is 0.004%), and the binder is cellulose ethers (percentage content is 0.01%), or modify the triterpene saponins to Codonopsis lanceolata saponin I (30% content), the binder is cellulose ether (50% content), or the triterpene saponins are modified to Codonopsis lanceolata saponin I (% content is 10%) ), the binder is cellulose ethers (percentage content is 10%), or the triterpene saponin is modified to Codonopsis lanceolata saponin I (percentage content is 0.1%), and the binder is cellulose ethers (percentage The content is 3%), the non-washing and protecting skin care products with the same properties can be obtained.
- Example 7 changing the types and contents of triterpene saponins, binders, excipients or active ingredients can achieve a disintegration time of 5s and a dissolution time of less than 12s. , The dissolution rate is greater than 95% in 50s.
- the packaging of the above Examples 1-3 can be double aluminum, aluminum plastic or high barrier polymer blister packaging, and the packaging of Examples 4-6 can be a glass or metal container with aluminum plastic seal or film seal.
- the packaging of Embodiment 7 may be a can of metal material.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Description
Claims (20)
- 一种冻干制剂,其特征在于,其中三萜皂苷在所述冻干制剂中质量百分数为0.004-95%,粘结剂在所述冻干制剂中的质量百分数为0.01-99%;所述冻干制剂由内含三萜皂苷和粘结剂的前配液冻干而成,其中:当三萜皂苷在前配液中的质量百分数为0.001%-50%时,粘结剂在前配液中的质量百分数为0.01%-50%,且三萜皂苷的质量随着粘结剂质量的增加而增加;当三萜皂苷在前配液中的质量百分数为50%-95%时,粘结剂在前配液中的质量百分数为0.01%-20%,且三萜皂苷的质量随着粘结剂的质量增加而减少。
- 一种冻干制剂,其特征在于,所述冻干制剂由内含三萜皂苷和粘结剂的前配液冻干而成,所述冻干制剂为口服制剂、固体饮料或非洗护用护肤品,当所述冻干制剂为口服制剂时,其中三萜皂苷在所述前配液中质量百分数为0.004%-50%,粘结剂在所述前配液中的质量百分数为0.01%-50%;当所述冻干制剂为固体饮料时,其中三萜皂苷在所述前配液中质量百分数为50%-95%,粘结剂在所述前配液中的质量百分数为0.01%-20%;当所述冻干制剂为非洗护用护肤品时,其中三萜皂苷在所述前配液中质量百分数为0.004-30%,粘结剂在所述前配液中的质量百分数为0.01-50%。
- 如权利要求2所述的冻干制剂,其特征在于,所述口服制剂的崩解时间小于3s,1min内溶出量大于90%,所述固体饮料的崩解时间小于10s,溶解时间小于15s,1min内溶出量大于90%。
- 如权利要求1或2所述冻干制剂,其特征在于,所述冻干制剂中还包括辅料,辅料在前配液中的质量百分数为0.01-50%,所述辅料为骨架支持剂、崩解剂、肤感改良剂、抗氧化剂、矫味剂、香精、跨黏膜、透皮吸收促进剂或pH调节剂中的一种或多种组合。
- 如权利要求1或2所述冻干制剂,其特征在于,所述冻干制剂中还包括活性成分,活性成分在前配液中的质量百分数为0.01-50%,所述活性成分为甾体皂苷、黄芪提取物、人参提取物、西洋参提取物、绞股蓝提取物、黄酮、参多糖、海参多糖、氨基酸、三七素、鹿茸多肽、白藜芦醇、珍珠粉、水解珍珠、林蛙油提取物、SOD或山楂提取物的一种或多种组合。
- 如权利要求1或2任一项所述的冻干制剂,其特征在于,所述粘结剂由冻干粘结剂 和/或低温粘结剂组成;所述冻干粘结剂选自人工或天然高分子聚合物、改性人工或天然高分子聚合物、无机物凝胶剂、多糖、多糖衍生物及其盐类、糖醇类、纤维素醚类、改性淀粉类、白蛋白或聚氨基酸中的一种或组合;所述低温粘结剂为C1-C16的醇、油脂、表面活性剂、人工或天然高分子聚合物或改性人工或天然高分子聚合物中的一种或组合。
- 如权利要求1或2所述的冻干制剂,其特征在于,所述三萜皂苷为酸性热敏性皂苷,优选为丙二酰基人参皂苷、绵毛黄芪苷、桔梗皂苷E、党参皂苷A-G、紫菀皂苷、Hb轮叶党参皂苷I-III或绞股蓝皂苷中的一种或组合。
- 如权利要求1或2所述的冻干制剂,其特征在于,所述三萜皂苷利用二氧化碳超临界萃取工艺和大孔树脂交换吸附的过程,从含皂苷药材中纯化取得,其包括以下步骤:1)取含皂苷药材,洗净,切碎,加入1~10倍的纯水;2)0℃~50℃低温环境下,对含皂苷药材碎块进行匀浆榨汁,得到汁A和渣B;3)取渣B,采用二氧化碳超临界萃取工艺,在-30℃~40℃下萃取时间30-100min,夹带剂为乙醇,得到萃取物C,弃去剩余残渣;4)取汁A,过大孔树脂柱,水洗去杂,30%~100%乙醇洗脱三萜皂苷,取样薄层色谱确定目标物,收集目标段,0℃~55℃下减压浓缩至无醇味,冷冻干燥,得到三萜皂苷1;5)取萃取物C,过大孔树脂柱,水洗去杂,30%~100%乙醇洗脱三萜皂苷,取样薄层色谱确定目标物,收集目标段,0℃~55℃下减压浓缩至无醇味,冷冻干燥,得到三萜皂苷2;6)分开使用或合并三萜皂苷1和2,得到最终三萜皂苷产物。
- 如权利要求8所述的冻干制剂,其特征在于,所述含皂苷药材为西洋参、人参、三七、绞股蓝、柴胡、党参、桔梗、远志、甘草、黄芪或商陆的一种植物或多种植物组合,所述含皂苷药材为植物的根部、茎叶或花中的一种或组合。
- 如权利要求1或2所述冻干制剂,其特征在于,通过以下步骤制备:a)将溶剂、三萜皂苷和粘结剂混合形成溶液、乳液或者悬浊液形式的前配液,或将溶剂、三萜皂苷、粘结剂和辅料混合形成溶液、乳液或者悬浊液形式的前配液后,定容、脱气;b)使用定量灌装泵,将a)得到的前配液注入到定量成型模具中,进行脱气;c)将b)得到侧产物冷冻干燥,除去溶剂,得到冻干制剂;或通过以下步骤制备:a)制备软冰混合物:将三萜皂苷、粘结剂与溶剂混合得到前配液,或和将三萜皂苷、 粘结剂、溶剂和辅料混合得到前配液,将前配液进行凝冻,得到软冰混合物1;b)将活性成分、粘结剂和溶剂混合得到前液,或活性成分、粘结剂、辅料和溶剂,与溶剂混合得到前配液,进行低温冷冻粉碎或低温喷雾,得到冰粉2;c)将活性成分、辅料,作为干粉3;d)将活性成分,作为干粉4;e)将软冰混合物1、冰粉2、干粉3或干粉4的一种或多种组合混合,得到的所有软冰混合物;f)使用一定模具定型,得到定型后的混合物5,脱模;g)对混合物5进行冷冻干燥,得到冻干制剂;或通过以下步骤制备:a)将溶剂、三萜皂苷和粘结剂混合形成溶液、乳液或者悬浊液形式的前配液,或将溶剂、三萜皂苷、粘结剂和辅料混合形成溶液、乳液或者悬浊液形式的前配液后,定容、脱气;b)使用定量灌装泵,在内部温度处于溶液共晶点以下的舱体内进行滴注,使其滴液时迅速冻结;c)将已冻结的溶液进行冷冻干燥,得到冻干制剂。
- 如权利要求1或2所述冻干制剂,其特征在于,所述冻干制剂可为但不限于片剂形状、球形、椭球形或者各种人物、动物、植物、食物、图形标识或卡通形象。
- 如权利要求1或2所述的冻干制剂在日用化学品、药品、保健品和食品中的应用。
- 内容物为如权利要求1或2所述冻干制剂的阻隔性包装。
- 如权利要求13所述的阻隔性包装,其特征在与,所述阻隔性包装为双铝、铝塑或高阻隔高分子泡罩装,带有铝塑封口或膜封口的玻璃或金属容器,或者金属材质的密封容器。
- 三萜皂苷在冻干制剂中的应用,其特征在于,所述三萜皂苷为热敏性酸性皂苷,所述热敏性酸性皂苷是结构中带有羧基且加热温度高于50℃时,损失率大于30%的三萜皂苷。
- 如权利要求15所述的应用,其特征在于,所述三萜皂苷利用二氧化碳超临界萃取工艺和大孔树脂交换吸附的过程,从含皂苷药材中纯化取得,其包括以下步骤:1)取含皂苷药材,洗净,切碎,加入1~10倍的纯水;2)0℃~50℃低温环境下,对含皂苷药材碎块进行匀浆榨汁,得到汁A和渣B;3)取渣B,采用二氧化碳超临界萃取工艺,在-30℃~40℃下萃取时间30-100min,夹带剂为乙醇,得到萃取物C,弃去剩余残渣;4)取汁A,过大孔树脂柱,水洗去杂,30%~100%乙醇洗脱三萜皂苷,取样薄层色谱确定目标物,收集目标段,0℃~55℃下减压浓缩至无醇味,冷冻干燥,得到三萜皂苷1;5)取萃取物C,过大孔树脂柱,水洗去杂,30%~100%乙醇洗脱三萜皂苷,取样薄层色谱确定目标物,收集目标段,0℃~55℃下减压浓缩至无醇味,冷冻干燥,得到三萜皂苷2;6)分开使用或合并三萜皂苷1和2,得到最终三萜皂苷产物。
- 如权利要求16所述的应用,其特征在于,所述含皂苷药材为西洋参、人参、三七、绞股蓝、柴胡、党参、桔梗、远志、甘草、黄芪或商陆的的一种植物或多种植物组合,所述含皂苷药材为植物的根部、茎叶或花中的一种或组合。
- 一种提取三萜皂苷的方法,其特征在于,包括以下步骤:1)取含皂苷药材,洗净,切碎,加入1~10倍的纯水;2)0℃~50℃低温环境下,对含皂苷药材碎块进行匀浆榨汁,得到汁A和渣B;3)取渣B,采用二氧化碳超临界萃取工艺,在-30℃~40℃下萃取时间30-100min,夹带剂为乙醇,得到萃取物C,弃去剩余残渣;4)取汁A,过大孔树脂柱,水洗去杂,30%~100%乙醇洗脱三萜皂苷,取样薄层色谱确定目标物,收集目标段,0℃~55℃下减压浓缩至无醇味,冷冻干燥,得到三萜皂苷1;5)取萃取物C,过大孔树脂柱,水洗去杂,30%~100%乙醇洗脱三萜皂苷,取样薄层色谱确定目标物,收集目标段,0℃~55℃下减压浓缩至无醇味,冷冻干燥,得到三萜皂苷2;6)分开使用或合并三萜皂苷1和2,得到最终三萜皂苷产物。
- 如权利要求18所述的方法,其特征在于,所述含皂苷药材为西洋参、人参、三七、绞股蓝、柴胡、党参、桔梗、远志、甘草、黄芪或商陆的的一种植物或多种植物组合,所述含皂苷药材为植物的根部、茎叶或花中的一种或组合。
- 一种冻干制剂的制备方法,其特征在于,通过以下步骤制备:a)将溶剂、三萜皂苷和粘结剂混合形成溶液、乳液或者悬浊液形式的前配液,或将溶剂、三萜皂苷、粘结剂和辅料混合形成溶液、乳液或者悬浊液形式的前配液后,定容、脱气;b)使用定量灌装泵,将a)得到的前配液注入到定量成型模具中,进行脱气;c)将b)得到侧产物冷冻干燥,除去溶剂,得到冻干制剂;或通过以下步骤制备:a)制备软冰混合物:将三萜皂苷、粘结剂与溶剂混合得到前配液,或和将三萜皂苷、粘结剂、溶剂和辅料混合得到前配液,将前配液进行凝冻,得到软冰混合物1;b)将活性成分、粘结剂和溶剂混合得到前液,或活性成分、粘结剂、辅料和溶剂,与溶剂混合得到前配液,进行低温冷冻粉碎或低温喷雾,得到冰粉2;c)将活性成分、辅料,作为干粉3;d)将活性成分,作为干粉4;e)将软冰混合物1、冰粉2、干粉3或干粉4的一种或多种组合混合,得到的所有软冰混合物;f)使用一定模具定型,得到定型后的混合物5,脱模;g)对混合物5进行冷冻干燥,得到冻干制剂;或通过以下步骤制备:a)将溶剂、三萜皂苷和粘结剂混合形成溶液、乳液或者悬浊液形式的前配液,或将溶剂、三萜皂苷、粘结剂和辅料混合形成溶液、乳液或者悬浊液形式的前配液后,定容、脱气;b)使用定量灌装泵,在内部温度处于溶液共晶点以下的舱体内进行滴注,使其滴液时迅速冻结;c)将已冻结的溶液进行冷冻干燥,得到冻干制剂。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19920436.3A EP3943089A4 (en) | 2019-03-21 | 2019-10-22 | FREEZE-DRIED FORMULATION, PROCESS FOR ITS PREPARATION AND ITS USE |
US17/593,444 US20220184106A1 (en) | 2019-03-21 | 2019-10-22 | Freeze-dried formulation, preparation method and application thereof |
JP2022504319A JP2022526687A (ja) | 2019-03-21 | 2019-10-22 | 凍結乾燥製剤及びその調製方法と応用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910217331.3 | 2019-03-21 | ||
CN201910217331.3A CN110025623A (zh) | 2019-03-21 | 2019-03-21 | 一种冻干制剂及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020186747A1 true WO2020186747A1 (zh) | 2020-09-24 |
Family
ID=67236444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/112445 WO2020186747A1 (zh) | 2019-03-21 | 2019-10-22 | 一种冻干制剂及其制备方法和应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220184106A1 (zh) |
EP (1) | EP3943089A4 (zh) |
JP (1) | JP2022526687A (zh) |
CN (1) | CN110025623A (zh) |
WO (1) | WO2020186747A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112697949A (zh) * | 2020-12-09 | 2021-04-23 | 浙江金城阜通制药有限公司 | 一种保元汤及其类似方提取物及制剂的薄层鉴别方法 |
WO2022268401A1 (de) * | 2021-06-22 | 2022-12-29 | Beiersdorf Ag | Substrate mit seifenwurzeln |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110025623A (zh) * | 2019-03-21 | 2019-07-19 | 李和伟 | 一种冻干制剂及其制备方法和应用 |
CN112245564A (zh) * | 2020-11-03 | 2021-01-22 | 哈尔滨医科大学 | 一种注射用血管生成抑肽冻干制剂及其冻干方法 |
CN116019773A (zh) * | 2021-10-27 | 2023-04-28 | 北京量子高科制药科技有限公司 | 一种苯磺酸氨氯地平冻干口腔崩解片及其制备方法 |
CN114343153A (zh) * | 2022-01-07 | 2022-04-15 | 湖北神农蜂语生物产业有限公司 | 冻干蜂王浆银耳羹 |
CN114805521B (zh) * | 2022-06-07 | 2022-12-16 | 成都润馨堂药业有限公司 | 西洋参多肽及其组合物及其在降血压、提高免疫中的应用 |
CN116158998A (zh) * | 2022-12-30 | 2023-05-26 | 江苏聚源医疗技术有限公司 | 光稳定的胶原/虾青素冻干品及其制备方法 |
CN116426391B (zh) * | 2023-03-28 | 2024-02-23 | 陕西省微生物研究所 | 一株出芽短梗霉Aureobasidium pullulans P1及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006069970A (ja) * | 2004-09-02 | 2006-03-16 | Yukihiro Hirose | 男性の更年期障害を予防する組成物およびそれを含有する飲食品 |
JP2006206557A (ja) * | 2005-01-31 | 2006-08-10 | Ota Isan:Kk | アルコール誘発性疾病予防、治療剤及びその製造方法 |
CN101084911A (zh) * | 2006-06-08 | 2007-12-12 | 中国科学院上海药物研究所 | 七叶皂苷钠冻干乳剂及其制备方法 |
CN105477024A (zh) * | 2015-12-21 | 2016-04-13 | 福建省健神生物工程有限公司 | 一种高浓度灵芝三萜及三萜皂苷复合提取方法 |
CN106137957A (zh) * | 2015-04-02 | 2016-11-23 | 苏州大学 | 一种齐墩果酸型皂苷脂微乳及其制备方法 |
CN106490136A (zh) * | 2016-10-11 | 2017-03-15 | 中国热带农业科学院南亚热带作物研究所 | 从番麻叶片中提取天然抑菌物质的方法、提取物及其应用 |
CN107233217A (zh) * | 2016-03-25 | 2017-10-10 | 李和伟 | 一种含有表面活性剂的冻干制剂及其洗护产品 |
CN110025623A (zh) * | 2019-03-21 | 2019-07-19 | 李和伟 | 一种冻干制剂及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6132726A (en) * | 1998-10-21 | 2000-10-17 | Hauser, Inc. | Process for removing impurities from natural product extracts |
WO2004019960A2 (en) * | 2002-08-28 | 2004-03-11 | Lupin Ltd. | Herbal extract comprising a mixture of saponins obtained from sapindus trifoliatus for anticonvulsant activity |
CN1250228C (zh) * | 2004-06-29 | 2006-04-12 | 北京科信必成医药科技发展有限公司 | 三七总皂苷口腔崩解片及其制备方法 |
CN1320896C (zh) * | 2005-04-13 | 2007-06-13 | 丽珠集团利民制药厂 | 一种调节免疫的参芪组合物及其制备方法 |
WO2006114775A2 (en) * | 2005-04-27 | 2006-11-02 | Tg Biotech | Treatment of insulin resistance syndrome |
CN1919223B (zh) * | 2005-08-23 | 2011-08-10 | 山东轩竹医药科技有限公司 | 三七总皂苷与七叶皂苷的药物组合物 |
US20070065526A1 (en) * | 2005-09-19 | 2007-03-22 | Gow Robert T | Methods and compositions comprising Panax species |
CN100506235C (zh) * | 2006-09-26 | 2009-07-01 | 贵州信邦远东药业有限公司 | 一种治疗脑血管疾病的冻干制剂 |
US8557311B2 (en) * | 2008-11-12 | 2013-10-15 | DRACO Natural Products | Gynostemma extract surfactant/cleaning agent/emulsifier/foaming agent and method of producing same |
GB201012539D0 (en) * | 2010-07-27 | 2010-09-08 | Savantium Ltd | Nutritional compositions |
US20140128582A1 (en) * | 2012-11-06 | 2014-05-08 | Zer-Ran YU | Continuous preparation method of ginseng ginsenosides and polysaccharides |
CN108567745A (zh) * | 2017-03-10 | 2018-09-25 | 常州柚盾实业投资有限公司 | 一种含有活性成分的冻干赋形制剂及其制备方法 |
AU2017422167B2 (en) * | 2017-07-07 | 2021-06-24 | Qi Liu | Preparation of Pulsatilla saponin B4 for injection |
CN107349244B (zh) * | 2017-08-30 | 2020-12-15 | 吉林农业大学 | 丙二酰基人参皂苷的提取方法 |
-
2019
- 2019-03-21 CN CN201910217331.3A patent/CN110025623A/zh active Pending
- 2019-10-22 US US17/593,444 patent/US20220184106A1/en active Pending
- 2019-10-22 EP EP19920436.3A patent/EP3943089A4/en not_active Withdrawn
- 2019-10-22 WO PCT/CN2019/112445 patent/WO2020186747A1/zh active Application Filing
- 2019-10-22 JP JP2022504319A patent/JP2022526687A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006069970A (ja) * | 2004-09-02 | 2006-03-16 | Yukihiro Hirose | 男性の更年期障害を予防する組成物およびそれを含有する飲食品 |
JP2006206557A (ja) * | 2005-01-31 | 2006-08-10 | Ota Isan:Kk | アルコール誘発性疾病予防、治療剤及びその製造方法 |
CN101084911A (zh) * | 2006-06-08 | 2007-12-12 | 中国科学院上海药物研究所 | 七叶皂苷钠冻干乳剂及其制备方法 |
CN106137957A (zh) * | 2015-04-02 | 2016-11-23 | 苏州大学 | 一种齐墩果酸型皂苷脂微乳及其制备方法 |
CN105477024A (zh) * | 2015-12-21 | 2016-04-13 | 福建省健神生物工程有限公司 | 一种高浓度灵芝三萜及三萜皂苷复合提取方法 |
CN107233217A (zh) * | 2016-03-25 | 2017-10-10 | 李和伟 | 一种含有表面活性剂的冻干制剂及其洗护产品 |
CN106490136A (zh) * | 2016-10-11 | 2017-03-15 | 中国热带农业科学院南亚热带作物研究所 | 从番麻叶片中提取天然抑菌物质的方法、提取物及其应用 |
CN110025623A (zh) * | 2019-03-21 | 2019-07-19 | 李和伟 | 一种冻干制剂及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3943089A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112697949A (zh) * | 2020-12-09 | 2021-04-23 | 浙江金城阜通制药有限公司 | 一种保元汤及其类似方提取物及制剂的薄层鉴别方法 |
CN112697949B (zh) * | 2020-12-09 | 2022-05-27 | 浙江金城阜通制药有限公司 | 一种保元汤及其类似方提取物及制剂的薄层鉴别方法 |
WO2022268401A1 (de) * | 2021-06-22 | 2022-12-29 | Beiersdorf Ag | Substrate mit seifenwurzeln |
Also Published As
Publication number | Publication date |
---|---|
EP3943089A1 (en) | 2022-01-26 |
CN110025623A (zh) | 2019-07-19 |
JP2022526687A (ja) | 2022-05-25 |
US20220184106A1 (en) | 2022-06-16 |
EP3943089A4 (en) | 2023-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020186747A1 (zh) | 一种冻干制剂及其制备方法和应用 | |
CA2480438C (en) | Novel use of the extract of processed ginseng and saponin isolated therefrom | |
EP3017821B1 (en) | Composition having a function for alleviating premenstrual syndrome and menstrual pain | |
CN107455531A (zh) | 一种冻干三七粉袋泡茶及其制备方法 | |
CN102058480B (zh) | 一种口服泡腾片及其制备方法 | |
CN106963737A (zh) | 一种易崩解的任意形态冻干成型制剂及其制备方法 | |
WO2007133054A1 (en) | A novel process for preparing black ginseng and the composition comprising the same | |
CN101757030A (zh) | 一种鹿茸全成分均一冻干制剂及其生产方法 | |
CN110393703A (zh) | 一种抗坏血酸的冻干赋形制剂及其制备方法 | |
JP2002291441A (ja) | アストラガリン含有食品 | |
CN106821770A (zh) | 一种制备任意形状的冻干制剂的方法及其产品 | |
CN104783180A (zh) | 一种金线莲冻干粉咀嚼片及其制备方法 | |
CN106929367A (zh) | 一种淡竹叶酒及其制备工艺方法 | |
CN104041617A (zh) | 一种排毒养颜奶茶的制备方法 | |
CN105941728A (zh) | 一种橘子皮泡腾茶饮颗粒 | |
CN106579410A (zh) | 玛咖参杞片及其制备方法 | |
CN105875935A (zh) | 一种薏仁祛湿泡腾茶饮片 | |
JP2000505786A (ja) | 新鮮な植物から貯蔵可能な製剤を製造する方法及び新鮮な植物製剤 | |
CN102217755B (zh) | 罗汉松实提取物制品的生产方法 | |
CN115554365A (zh) | 一种包含天麻提取物的冻干制剂及其制备方法和应用 | |
CN101757031A (zh) | 一种鹿茸全成分均一冻干制剂及其生产方法 | |
CN1051001C (zh) | 枸杞精细粉及由枸杞精细粉制得的枸杞精油 | |
TW201729825A (zh) | 含有人參花軸萃取物之促進毛髮生長或預防脫髮的組合物 | |
CN101095709A (zh) | 田七花叶泡腾片及制备方法 | |
CN102511715A (zh) | 罗汉果泡腾片及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19920436 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022504319 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019920436 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2019920436 Country of ref document: EP Effective date: 20211021 |